THU0581 Use of biological therapies in adult patients diagnosed with juvenile idiopathic arthritis: results from biobadaser, the spanish registry of adverse events with biologic therapies

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 491
• Main Authors: Bethencourt Baute, J.J., Sanchez-Piedra, C., Sanchez-Alonso, F., Ruiz-Montesinos, D., Manero, J., Rodriguez-Lozano, C., Perez-Pampin, E., Ortiz, A., Manrique, S., Hernandez, M.V., Campos, C., Sellas, A., Sifuentes, A., García-González, J., Gomez-Reino, J.J., Díaz-Gonzalez, F., Bustabad-Reyes, S.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2018
• Subjects: Age; Arthritis; Children; Clinical trials; Medical prognosis; Patients; Remission; Rheumatic diseases; Survival
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2018-eular.5942

BackgroundJuvenile idiopathic arthritis (JIA) is the most frequent chronic rheumatic disease in childhood. The early disease recognition and treatment is critical to prevent long-term complications and disability in childhood. During the last decade the arrivals of biologics has dramatically changed the prognosis of these patients. A number of well-designed clinical trials, as well as cohort studies have demonstrated that biologics are an effective option for JIA patients who do not respond or cannot tolerate treatment with synthetic disease modifying drugs (DMARDs).JIA is not confined to childhood, and a 41% had active disease are on medication after 30 years and 28% had a high symptom state.ObjectivesThe aim of this work was to study the pattern of use, drug survival and adverse events of biologic therapy in JIA patients during the transition period from the diagnostic to the adulthood.MethodsInformation was obtained from BIOBADASER, a safety multicenter prospective registry. All patients included in the registry diagnosed of JIA between 2000 and 2015 were analysed. Proportions, means and standard deviations (SD) were used to describe population. Incidence rates and 95% confidence intervals were calculated to assess adverse events. Kaplan-Meier analysis was used to compare the drug survival.Results469 patients, 46.1% women were included in this study. Age at diagnosis was 9.4 (SD=5.3) and years of disease evolution 24.1 (SD=14.1). The age at biological treatment initiation was 23.9 years (SD=13.9). The pattern of use of biologics in JIA patients in the paediatric age shows a linear increase from 24% in 2000 to 65% in 2014. Interestingly, the biologic suspension for disease remission was higher in patients who initiated its use under 16 years (25.7%) than in those who began at 16 years or later (7.9%, p<0.0001). Serious adverse events showed a total incidence rate of 41.4 (35.2–48.7) (1000 patients/year) without differences between patients younger or older than 16 years old. However, patients younger than 16 years old showed a significant increment in infeccion and infectation (p<0.001).ConclusionsThe biologic survival and suspension by remission was higher when the biologic therapy started before 16 years old in JIA patients. The incidence rate severe adverse events in the childhood and adulthood in JIA patients treated with biologics was similar, however, a significant increment of infection was observed in patients under 16 years old.Disclosure of InterestNone declared